US Patent

US9549929 — Pyrrolo[2,3-D]pyrimidine derivatives

Method of Use · Assigned to Pfizer Inc · Expires 2034-02-19 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pyrrolo[2,3-D]pyrimidine derivatives used as Janus Kinase (JAK) inhibitors.

USPTO Abstract

Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.

Drugs covered by this patent

chembl-chembl3655081 (ABROCITINIB)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3195`	—	chembl-chembl3655081
`U-3195`	—	chembl-chembl3655081
`U-3195`	—	chembl-chembl3655081

Patent Metadata

Patent number: US9549929
Jurisdiction: US
Classification: Method of Use
Expires: 2034-02-19
Drug substance claim: No
Drug product claim: No
Assignee: Pfizer Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.